|

Lutetium Lu 177 Dotatate Clinical Trials

8 actively recruiting trials across 6 locations

Also known as: 177 Lu-DOTA-TATE, 177 Lu-DOTA-TATE, 177 Lu-DOTA-Tyr3-Octreotate, 177Lu-DOTA0-Tyr3-Octreotate, 437608-50-9, Lutathera, Lutetium (177Lu) Oxodotreotide, 177 Lu-DOTA-TATE, 177 Lu-DOTA-Tyr3-Octreotate, 177Lu-DOTA0-Tyr3-Octreotate, Lutathera, Lutetium (177Lu) Oxodotreotide, Lutetium Lu 177 DOTA(0)-Tyr(3)-Octreotate, Lutetium Lu 177 Dotatate, 177 Lu-DOTA-Tyr3-Octreotate, 177Lu-DOTA0-Tyr3-Octreotate, Lutathera, Lutetium (177Lu) Oxodotreotide, Lutetium Lu 177 DOTA(0)-Tyr(3)-Octreotate, Lutetium Lu 177-DOTA-Tyr3-Octreotate, Lutetium Lu 177-DOTA-Tyr3-Octreotate,Lutetium Oxodotreotide Lu-177, Lutetium Oxodotreotide Lu-177, PRRT, lutetium Lu 177-DOTATATE

Birmingham, Alabama2 trials

Comparing Retreatment of 177Lu-DOTATATE PRRT Versus the Usual Treatment in Patients With Metastatic Unresectable Gastroenteropancreatic Neuroendocrine Tumors, NET RETREAT Trial

University of Alabama at Birmingham Cancer Center

Phase 2
Testing Lutetium Lu 177 Dotatate in Patients With Somatostatin Receptor Positive Advanced Bronchial Neuroendocrine Tumors

University of Alabama at Birmingham Cancer Center

Phase 2

Duarte, California2 trials

Testing the Addition of Sunitinib Malate to Lutetium Lu 177 Dotatate (Lutathera) in Pancreatic Neuroendocrine Tumors

City of Hope Comprehensive Cancer Center

Phase 1
Testing the Safety and Effectiveness of Radiation-based Treatment (Lutetium Lu 177 Dotatate) for Metastatic Prostate Cancer That Has Neuroendocrine Cells

City of Hope Comprehensive Cancer Center

Phase 2

Atlanta, Georgia1 trial

Combination External Radiation and PRRT for Large GI Neuroendocrine Tumors.

Emory University Hospital Midtown

Phase 1

Iowa City, Iowa1 trial

Phase II Study of Peptide Receptor Radionuclide Therapy in Combination With Immunotherapy for Patients With Merkel Cell Cancer

University of Iowa Hospitals and Clinics

Phase 2

Rochester, Minnesota1 trial

Lutathera for the Treatment of Inoperable, Progressive Meningioma After External Beam Radiation Therapy

Mayo Clinic in Rochester

Phase 2

Nashville, Tennessee1 trial

Surgical Debulking Prior to Peptide Receptor Radionuclide Therapy in Well Differentiated Gastroenteropancreatic Neuroendocrine Tumors

Vanderbilt University/Ingram Cancer Center

Phase 4

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.